Has Siamak Saadat, MD received payments from drug or device companies?

Yes. Drug and device makers reported $634,939 in general payments to Siamak Saadat, MD across 2,084 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Siamak Saadat, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Siamak Saadat, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Siamak Saadat, MD

Hematology & Oncology · Colton, CANPI 1992018642

Payments from drug & device makers

$634,939in general payments, 2019–2025

Across 2,084 payments — averaging $304.67 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

E.r. Squibb & Sons, L.L.C.$253K
Sobi, Inc$98K
Dova Pharmaceuticals$84K
Lilly USA, LLC$54K
Amgen$40K
Pfizer$25K
plus $81K from 54 others

What the payments were for

Consulting fees$34,2855%
Speaking & faculty fees$498,30978%
Travel & lodging$62,56210%
Food & beverage$39,5166%
Education$2680%

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
E.r. Squibb & Sons, L.L.C.	294	$253,028
Sobi, Inc	95	$98,082
Dova Pharmaceuticals	92	$83,946
Lilly USA, LLC	115	$53,901
Amgen	89	$40,030
Pfizer	156	$24,965
Taiho Oncology, Inc.	53	$22,647
Novartis	153	$21,475
Global Blood Therapeutics, Inc.	16	$6,583
Gilead(2 entities)	45	$3,248
Array Biopharma Inc	20	$2,909
AstraZeneca(2 entities)	83	$2,880
Bristol Myers Squibb	48	$2,467
Merck	98	$2,290
Johnson & Johnson(2 entities)	93	$2,189
Dendreon Pharmaceuticals LLC	29	$1,961
Genentech USA, Inc.	82	$1,409
Sanofi	45	$861
Astellas Pharma US Inc	47	$783
Incyte Corporation	31	$673
Bayer	32	$630
Eisai Inc.	27	$618
GSK	26	$554
AVEO Pharmaceuticals, Inc.	18	$545
Beigene USA, Inc.	19	$447
Puma Biotechnology, Inc.	17	$417
Exelixis Inc.	23	$398
Regeneron Healthcare Solutions, Inc.	13	$367
Boehringer Ingelheim	19	$358
Seagen Inc.	14	$337
Takeda Pharmaceuticals U.S.A., Inc.	11	$327
EMD Serono, Inc.	15	$293
AbbVie	13	$280
Pharmacyclics LLC, An Abbvie Company	15	$273
Karyopharm Therapeutics Inc.	12	$266
Sumitomo Pharma America, Inc.	11	$191
Ipsen Biopharmaceuticals, Inc	10	$182
Myovant Sciences Inc.	10	$176
Springworks Therapeutics, Inc.	7	$171
Tesaro, Inc.	12	$165
Daiichi Sankyo Inc.	8	$160
ADC Therapeutics America, Inc.	7	$146
Agios Pharmaceuticals, Inc.	6	$137
Beone Medicines USA, Inc.	4	$100
Pharmaessentia USA Corporation	4	$86
Terumo BCT, Inc.	5	$68
Emmaus Medical, Inc.	4	$66
Tolmar Pharmaceuticals, Inc.	3	$58
Iovance Biotherapeutics, Inc.	2	$57
Rigel Pharmaceuticals, Inc.	2	$52
Legend Biotech USA Inc.	2	$52
Menarini Silicon Biosystems, Inc.	2	$52
Secura Bio, Inc.	3	$49
Mylan Institutional Inc.	2	$48
Tempus AI, Inc	2	$47
Adaptive Biotechnologies Corporation	2	$46
Servier Pharmaceuticals LLC	2	$44
Myriad Genetic Laboratories, Inc.	2	$42
Teva Pharmaceuticals USA, Inc.	2	$38
Stemline Therapeutics Inc.	2	$33

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

OPDIVO$230,511
DOPTELET$179,015
IMDELLTRA (AMG 757)$38,526
VERZENIO$32,234
Lonsurf$21,746
ERBITUX$17,598
OXBRYTA$11,202
TIVDAK$5,792
ORGOVYX$5,142
ADAKVEO$4,739
XTANDI$3,900
PROMACTA$3,155
BRAFTOVI$2,520
Tecartus$2,300
PROVENGE$1,340
IMFINZI$1,150

How this compares

$634,939 in reported general payments places this provider in the 85th percentile of 1,363 hematology & oncology providers in California.

See all hematology & oncology providers in California →

Medicare billing

Part B allowed, 2024

$73,365

Medicare patients

171

Services billed

765

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
Anastrozole	40	$347
Ondansetron Hcl	26	$173
Tamoxifen Citrate	15	$166
Letrozole	11	$120

Paid to pharmacies, not to this prescriber.

Other hematology & oncology in Colton

Alain AlgaziSan Francisco$119.2M
David BerzLos Angeles$43.3M
Jonathan GoldmanSanta Monica$35.7M
Omid HamidSanta Monica$23.7M
Nicholas McAndrewLos Angeles$22.9M
Aditya BardiaSanta Monica$22.1M
Joseph TuscanoSacramento$20.4M
Zev WainbergSanta Monica$19.3M
Caitlin CostelloSan Diego$16.9M
Rana McKaySan Diego$15.3M

See the full list for California →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →